Ensysce Biosciences Inc

ENSC

Company Profile

  • Business description

    Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.

  • Contact

    7946 Ivanhoe Avenue
    Suite 201
    La JollaCA92037
    USA

    T: +1 858 263-4196

    https://www.ensysce.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    8

Stocks News & Analysis

stocks

Plunge in ASX share unwarranted

Weak result distracts from improving trading and cost outlook.
stocks

Oracle shares are up 87% in 2025. Is it a buy?

Oracle’s cloud database business is riding the AI wave.
stocks

Bumper crop to benefit ASX listed share

We raise our earnings forecast 11% for next year.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,137.8014.900.16%
CAC 407,872.0241.910.54%
DAX 4023,611.3384.280.36%
Dow JONES (US)46,292.7888.76-0.19%
FTSE 1009,223.323.36-0.04%
HKSE26,159.12185.02-0.70%
NASDAQ22,573.47215.50-0.95%
Nikkei 22545,493.66447.850.99%
NZX 50 Index13,129.586.96-0.05%
S&P 5006,656.9236.83-0.55%
S&P/ASX 2008,845.9014.300.16%
SSE Composite Index3,821.836.74-0.18%

Market Movers